Fewer than one in 10 individuals who could benefit from obesity jabs such as Wegovy can access them, states the WHO as it releases its first guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for more widespread and fairer availability to this class of drugs.
Based on forecasts, over two billion could be obese by 2030 without intervention.
"The new guidelines acknowledges that excess weight is a chronic disease that can be treated with holistic and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major obstacles to universal access to the injections that can assist patients in reducing significant weight, explains the body.
GLP-1 Therapy Scarcity
Even in the current most favorable scenario, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – less than 10% of those who need them, as stated by the health organization.
The advice calls on countries and companies to expand availability, through approaches like licensing agreements.
The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Jabs Operate
GLP-1 drugs mimick a biological compound to delay gastric emptying, suppress the appetite and enhance the sense of being full so users eat less.
People typically begin shedding pounds after several weeks of commencing the weekly injections.
Evidence indicates patients may regain a significant portion a year later of halting the medication, when their usual appetite come back.
To be above a healthy weight increases your likelihood for developing diseases, such as type 2 diabetes, heart disease, stroke, and some malignancies.
Excess weight impacts individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
